FDA reduces monitoring time for Amgen’s Imdelltra infusions

The FDA has approved an update to the prescribing information for Amgen’s Imdelltra, cutting the recommended monitoring time for ES-SCLC patients after their first two infusions.

The post FDA reduces monitoring time for Amgen’s Imdelltra infusions appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.